Search This Blog

Tuesday, December 6, 2022

Goldman Sachs on hunt for bargain crypto firms after FTX fiasco

 Goldman Sachs plans to spend tens of millions of dollars to buy or invest in crypto companies after the collapse of the FTX exchange hit valuations and dampened investor interest.

FTX's implosion has heightened the need for more trustworthy, regulated cryptocurrency players, and big banks see an opportunity to pick up business, Mathew McDermott, Goldman's head of digital assets, told Reuters.

Goldman is doing due diligence on a number of different crypto firms, he added, without giving details.

"We do see some really interesting opportunities, priced much more sensibly," McDermott said in an interview last month.

FTX filed for Chapter 11 bankruptcy protection in the United States on Nov. 11 after its dramatic collapse, sparking fears of contagion and amplifying calls for more crypto regulation.

"It's definitely set the market back in terms of sentiment, there's absolutely no doubt of that," McDermott said. "FTX was a poster child in many parts of the ecosystem. But to reiterate, the underlying technology continues to perform."

While the amount Goldman may potentially invest is not large for the Wall Street giant, which earned $21.6 billion last year, its willingness to keep investing amid the sector shakeout shows it senses a long term opportunity.

Its CEO David Solomon told CNBC on Nov. 10, as the FTX drama was unfolding, that while he views cryptocurrencies as "highly speculative", he sees much potential in the underlying technology as its infrastructure becomes more formalized.

Rivals are more sceptical.

"I don't think it's a fad or going away, but I can't put an intrinsic value on it," Morgan Stanley CEO James Gorman said at the Reuters NEXT conference on Dec. 1.

HSBC CEO Noel Quinn, meanwhile, told a banking conference in London last week he has no plans to expand into crypto trading or investing for retail customers.

Chinese hackers stole millions worth of U.S. COVID relief money, Secret Service says

 Chinese hackers have stolen tens of millions of dollars worth of U.S. COVID relief benefits since 2020, the Secret Service said on Monday.

The Secret Service declined to provide any additional details but confirmed a report by NBC News that said the Chinese hacking team that is reportedly responsible is known within the security research community as APT41 or Winnti.

APT41 is a prolific cybercriminal group that had conducted a mix of government-backed cyber intrusions and financially motivated data breaches, according to experts.

Several members of the hacking group were indicted in 2019 and 2020 by the U.S. Justice Department for spying on over 100 companies, including software development companies, telecommunications providers, social media firms, and video game developers.

"Regrettably, the Chinese Communist Party has chosen a different path of making China safe for cybercriminals so long as they attack computers outside China and steal intellectual property helpful to China," former Deputy Attorney General Jeffrey Rosen said at the time.

The Chinese embassy in Washington did not immediately respond to a request for comment.

https://www.yahoo.com/news/chinese-hackers-stole-millions-worth-163328232.html

Beijing drops COVID testing burden as wider easing beckons

 Tests no longer needed for supermarkets, offices

*

Latest in a mix of nationwide easing steps

*

Curbs sparked widespread protests last month

*

New national rules due as soon as Weds - sources

People in China's capital Beijing were allowed to enter parks, supermarkets, offices and airports without showing proof of a negative COVID-19 test on Tuesday, the latest in a mix of easing steps nationwide after last month's historic protests.

"Beijing readies itself for life again" read a headline in the government-owned China Daily newspaper, adding that people were "gradually embracing" their newfound freedoms.

Authorities have been loosening some of the world's toughest COVID curbs to varying degrees and softening their tone on the threat of the virus, in what many hope could herald a more pronounced shift towards normalcy three years into the pandemic.

"This might be the first step towards reopening from this pandemic," Hu Dongxu, 27, told Reuters as he swiped his travel card to enter a train station in Beijing, which has also dropped the need for tests to ride the subway.

Both of the city's airports also no longer require people to test to enter the terminal, state media reported on Tuesday, although there was no indication of changes to rules requiring passengers to show negative tests prior to boarding.

But further loosening beckons after a string of protests last month that marked the biggest show of public discontent in mainland China since President Xi Jinping took power in 2012.

China may announce 10 new national easing measures as early as Wednesday, two sources with knowledge of the matter told Reuters.

The prospect of further relaxation of the rules has sparked optimism among investors that the world's second biggest economy would regather strength, and help to boost global growth.

Facebook owner Meta may remove news from platform if U.S. Congress passes media bill

 Facebook parent Meta Platforms Inc on Monday threatened to remove news from its platform if the U.S. Congress passes a proposal aimed at making it easier for news organizations to negotiate collectively with companies like Alphabet Inc's Google and Facebook.

Sources briefed on the matter said lawmakers are considering adding the Journalism Competition and Preservation Act to a must-pass annual defense bill as way to help the struggling local news industry. Meta spokesperson Andy Stone in a tweet said the company would be forced to consider removing news if the law was passed "rather than submit to government-mandated negotiations that unfairly disregard any value we provide to news outlets through increased traffic and subscriptions."

He added the proposal fails to recognize that publishers and broadcasters put content on the platform because "it benefits their bottom line - not the other way around."

The News Media Alliance, a trade group representing newspaper publishers, is urging Congress to add the bill to the defense bill, arguing that "local papers cannot afford to endure several more years of Big Tech’s use and abuse, and time to take action is dwindling. If Congress does not act soon, we risk allowing social media to become America’s de facto local newspaper."

More than two dozen groups including the American Civil Liberties Union, Public Knowledge and the Computer & Communications Industry Association on Monday urged Congress not to approve the local news bill saying it would "create an ill-advised antitrust exemption for publishers and broadcasters" and argued the bill does not require "funds gained through negotiation or arbitration will even be paid to journalists."

A similar Australian law, which took effect in March 2021 after talks with the big tech firms led to a brief shutdown of Facebook news feeds in the country, has largely worked, a government report said.

Since the News Media Bargaining Code took effect, various tech firms including Meta and Alphabet have signed more than 30 deals with media outlets, compensating them for content that generated clicks and advertising dollars, the report added.

https://www.yahoo.com/lifestyle/facebook-owner-meta-remove-news-213955257.html

Kinarus KIN001 Shows Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5

 Kinarus TherapeuticsKIN001Shows Strong Antiviral ActivityAgainst SARS-CoV-2Omicron Subvariants BA.2 and BA.5

  • Researchersat Friedrich-Alexander-Universität Erlangen-Nürnberg and Kinarus report newantiviral data of KIN001 against SARS-CoV-2Omicron BA.2 and BA.5 subvariants
  • KINFAST Phase 2 trial of KIN001 in ambulatory COVID-19 patients is actively recruiting

Valneva Hosts Investor Day in New York City - December 06, 2022

  Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, is hosting an in-person investor day today in New York City to discuss the Company’s current vaccine pipeline, commercial products, and future directions. Valneva’s Chief Executive Officer Thomas Lingelbach, Chief Financial Officer Peter Bühler, and other members of the Company’s senior leadership team will highlight Valneva’s core near- and mid-term value drivers, including its early- and late-stage development pipeline and commercial vaccine business.

Presentations will begin at 10am Eastern Time. The event will also be webcast live and archived on the Events and Presentations page in the Investors section of Valneva’s website. A live Q&A session will follow the formal presentations with opportunity for virtual attendees to participate. To register for the event, please click here.

Valneva will highlight its late-stage clinical and select preclinical vaccine candidates:

  • VLA15, a Lyme Borreliosis (Lyme disease) vaccine candidate that is partnered with Pfizer for global development and commercialization, currently enrolling a pivotal Phase 3 study
  • VLA1553, a chikungunya virus vaccine candidate for which rolling submission of a Biologics License Application (BLA) is nearing completion
  • VLA1554, a proprietary recombinant protein subunit candidate comprised of stabilized pre-fusion F peptide as a potential prophylactic vaccine against the respiratory pathogen human metapneumovirus (hMPV)
  • VLA2112, a recombinant protein subunit candidate comprised of a mix of relevant antigens as a potential second-generation prophylactic vaccine against Epstein-Barr virus (EBV)

Valneva will also provide a detailed overview of its current commercial products and the factors driving continued recovery and potential growth of this part of the business as the COVID-19 pandemic slows, followed by a brief financial overview.

Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia

 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it will host a webcast on Monday, December 12, 2022, at 10:00 a.m. ET to discuss new data from the TakeAim Leukemia trial of emavusertib, including data presented at the 64th American Society of Hematology Annual Meeting.

This presentation will include data for 28 additional evaluable AML/MDS patients:

  • 11 patients treated with monotherapy in targeted populations (now 24 patients total)
  • 13 patients treated with monotherapy in non-target populations (now 34 patients total)
  • 4 patients treated with the combination of emavusertib and venetoclax (4 patients total)

Patients in a targeted population are those with FLT3, U2AF1, or SF3B1 mutations.

The call led by James Dentzer, President and CEO, will include a presentation by Robert Martell, M.D., Head of Curis R&D and commentary by Eric Winer, M.D., Clinical Investigator at the Dana-Farber Cancer Institute. The speakers and additional members of Curis leadership will be available to answer questions at the end of the event.

To access the live call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 10:00 a.m. ET.

A live webcast will be available under "Events & Presentations" in the Investors section of the Company's website at www.curis.com. A replay of the webcast will be available on the Curis website shortly after completion of the call.

https://www.biospace.com/article/releases/curis-to-host-webcast-to-discuss-updated-emavusertib-clinical-data-in-leukemia/